{"prompt": "['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 19 of 115', 'Rheumatic heart disease', 'Thrombocytosis, thrombocytopenia', 'Any condition contraindicating chronic anticoagulation', 'Active systemic infection', 'Hypertrophic cardiomyopathy', 'Cryoglobulinemia', 'Uncontrolled hyperthyroidism', 'Any cerebral ischemic event (strokes or TIAs) which occurred during the 6 month', 'interval preceding the consent date', 'Any woman known to be pregnant or breastfeeding, or any woman of child', 'bearing potential who is not on a reliable form of birth regulation method or', 'abstinence', 'Life expectancy less than one year', 'Current or anticipated participation in any other clinical trial of a drug, device or', 'biologic during the duration of the study not pre-approved by Medtronic', 'Known allergies or hypersensitivities to adhesives', 'Known drug or alcohol dependency', 'Unwilling or unable to comply fully with study procedures and follow-up', 'Study Procedures', 'Subjects are assessed for eligibility at a baseline visits and then undergo a', 'and Assessments', 'cryoablation procedure followed by hospital discharge. All subjects are contacted by', 'phone 6 weeks after the ablation procedure, are seen in the office at 3, 6 and 12', 'months after the index ablation procedure, and are then exited from the study.', '6. Introduction', '6.1.', 'Background', 'Atrial fibrillation is a common and disabling cardiac arrhythmia with a heterogeneous clinical presentation.', 'The fundamental pathophysiology consists of atrial wavelets propagating in different directions, causing', 'disorganized atrial depolarizations without effective atrial contraction, with concomitant rapid and irregular', 'ventricular contractions. AF can be clinically stratified based on whether episodes are self-terminating', '(paroxysmal) or persistent. Paroxysmal AF (PAF) is defined as recurrent AF (>2 episodes) that terminates', 'spontaneously within 7 days. Persistent AF is defined as continuous AF that is sustained for greater than 7', 'days. 1', '1', 'Calkins, H., et al., HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation:', 'recommendations for Patient selection, procedural techniques and follow-up, definitions, endpoints and research trial', 'design. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation.', 'Heart Rhythm. 2012; 9(4): p. 632-696.e20.', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 20 of 115', 'AF is the most common of the sustained arrhythmias affecting millions of people worldwide. In the US, AF', 'affects between 2.7 million and 6.1 million adults\u00b2, and that number is expected to double over the next 25', 'years. 3 Prolonged AF may lead to electrical, mechanical, and structural changes to the left atrium, which may', 'then progress to tachycardia-induced cardiomyopathy, heart failure and persistent AF. Persistent AF', 'represents approximately 25% of AF cases. 4 The prognosis is related to the underlying cause of the disease,', 'with idiopathic causes having the best prognosis and ischemic cardiomyopathy having a poor prognosis. The', 'mortality rate in patients with AF is twice that of patients without AF, and the risk of AF-related stroke is 5-', 'fold compared to the risk in patients without AF. 5 In comparison to patients with PAF, patients with', 'persistent AF are at a significantly greater risk for cardiac mortality (hazard ratio [HR], 2.37;95% confidence', 'interval [CI], 1.19-4.73) and all-cause mortality (HR, 1.89; CI, 1.30-2.74).6', 'In the US, approved treatment options for patients with persistent AF are presently limited to', 'pharmaceutical therapy and concomitant surgical ablation, which are unsatisfactory for many patients with', 'AF. Per the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation,', '\"Antiarrhythmic drug (AAD) efficacy is modest and asymptomatic AF recurrences are common\". 2 All AADs', 'may result in adverse events requiring therapy discontinuation and, with the exceptions of amiodarone and', 'propafenone, increase the likelihood of proarrhythmia.\u00b2 Side effects for AADs include bradycardia,', 'palpitations, fatigue, dizziness, nausea and vomiting, stomach pain, constipation and diarrhea, rash, vision', 'problems, and urinary retention. However, there is a growing body of evidence supporting catheter ablation', 'as a reasonable option for treating persistent AF patients. In 2012, the HRS/EHRA/ECAS Expert Consensus', 'Statement on Catheter and Surgical Ablation of Atrial Fibrillation published a Class lla Level B', 'recommendation for catheter and surgical ablation of AF for persistent symptomatic AF (refractory or', 'intolerant to at least one Class I or III AAD), stating \"the benefits of an AF ablation procedure exceed the', 'risks\". 1 In the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation, the level', 'of evidence supporting the recommendation moved to Class lla, Level A. 2', 'Catheter ablation treatment strategies for AF have evolved over time and currently include pulmonary vein', 'isolation (PVI) as a cornerstone of ablation therapy in all types of AF (paroxysmal and persistent). 7, 8 AF arises', 'primarily from the left side of the heart in (or near) the atrium, particularly where the pulmonary veins (PVs)', '2 January C, Wann L, Alpert J, Calkins H, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial', 'fibrillation: a report of the American College of Cardiology/Americar Heart Association Task Force on Practice Guidelines', 'and the Heart Rhythm Society. J Am Coll Cardiol. 2014.', '3 Go A, Hylek E, Phillips K, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm', 'Management and Stroke Prevention: the An Ticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA.', '2001;285(18): 2370-2375.', '4', 'Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clinical', 'Epidemiology. 2014;6:213-220 doi:10.2147/CLEP.S47385', '5', 'Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke.', '1991;22(8):983-988.', '6 Ghanbari H, Baser K, Jongnarangsin K, et al. Mortality and cerebrovascular events after radiofrequency catheter', 'ablation of atrial fibrillation. Heart Rhythm. 2014;11:1503-1511.', '7', 'Raviele et al. Venice Chart International consensus Document on Atrial Fibrillation: 2011 Update. J Cardiovasc', 'Electrophysiol, 2012;23:890-923.', '8', \"Jais P, O'Neill MD, Takahashi Y, et al. Stepwise Catheter Ablation of Chronic Atrial Fibrillation: Importance of Discrete\", 'Anatomic Sites for Termination. J Cardiovaso Electrophysiol. 2006;17 S28-S36, Suppl. 3.', 'Version 4, 10NOVO016', 'Confidential']\n\n###\n\n", "completion": "END"}